Galgenprostucel-L/litgenprostucel-L: Prostate cancer vaccine

Z. Al-Kadhimi, E. I. Heath

Research output: Contribution to journalReview article

Abstract

Prostate cancer is the second leading cause of cancer death in men in the United States. Men with metastatic prostate cancer are treated initially with androgen deprivation therapy, and upon developing castrate-resistant disease they are treated with docetaxel-based chemotherapy (1, 2). There is a clear need for additional treatment options for patients with advanced prostate cancer, especially options with the potential to provide greater efficacy with minimal toxicity. One such treatment option utilizes the power of the patient's own immune system to recognize and fight the malignant prostate cancer cells. The strategy of therapeutic vaccines in prostate cancer treatment has been actively pursued in recent years. In this monograph, we will review the role of GVAX® immunotherapy for prostate cancer, a cancer immunotherapy utilizing irradiated whole tumor cells genetically modified to secrete an important immunostimulating cytokine, human granulocyte-macrophage colony-stimulating factor (GM-CSF).

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalDrugs of the Future
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Cancer Vaccines
Prostatic Neoplasms
docetaxel
Immunotherapy
Therapeutics
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Androgens
Cause of Death
Immune System
Vaccines
Cytokines
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Galgenprostucel-L/litgenprostucel-L : Prostate cancer vaccine. / Al-Kadhimi, Z.; Heath, E. I.

In: Drugs of the Future, Vol. 34, No. 1, 01.01.2009, p. 16-22.

Research output: Contribution to journalReview article

@article{518afa97fd8f4ddca9d6416666485310,
title = "Galgenprostucel-L/litgenprostucel-L: Prostate cancer vaccine",
abstract = "Prostate cancer is the second leading cause of cancer death in men in the United States. Men with metastatic prostate cancer are treated initially with androgen deprivation therapy, and upon developing castrate-resistant disease they are treated with docetaxel-based chemotherapy (1, 2). There is a clear need for additional treatment options for patients with advanced prostate cancer, especially options with the potential to provide greater efficacy with minimal toxicity. One such treatment option utilizes the power of the patient's own immune system to recognize and fight the malignant prostate cancer cells. The strategy of therapeutic vaccines in prostate cancer treatment has been actively pursued in recent years. In this monograph, we will review the role of GVAX{\circledR} immunotherapy for prostate cancer, a cancer immunotherapy utilizing irradiated whole tumor cells genetically modified to secrete an important immunostimulating cytokine, human granulocyte-macrophage colony-stimulating factor (GM-CSF).",
author = "Z. Al-Kadhimi and Heath, {E. I.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1358/dof.2009.034.01.1317459",
language = "English (US)",
volume = "34",
pages = "16--22",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Galgenprostucel-L/litgenprostucel-L

T2 - Prostate cancer vaccine

AU - Al-Kadhimi, Z.

AU - Heath, E. I.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Prostate cancer is the second leading cause of cancer death in men in the United States. Men with metastatic prostate cancer are treated initially with androgen deprivation therapy, and upon developing castrate-resistant disease they are treated with docetaxel-based chemotherapy (1, 2). There is a clear need for additional treatment options for patients with advanced prostate cancer, especially options with the potential to provide greater efficacy with minimal toxicity. One such treatment option utilizes the power of the patient's own immune system to recognize and fight the malignant prostate cancer cells. The strategy of therapeutic vaccines in prostate cancer treatment has been actively pursued in recent years. In this monograph, we will review the role of GVAX® immunotherapy for prostate cancer, a cancer immunotherapy utilizing irradiated whole tumor cells genetically modified to secrete an important immunostimulating cytokine, human granulocyte-macrophage colony-stimulating factor (GM-CSF).

AB - Prostate cancer is the second leading cause of cancer death in men in the United States. Men with metastatic prostate cancer are treated initially with androgen deprivation therapy, and upon developing castrate-resistant disease they are treated with docetaxel-based chemotherapy (1, 2). There is a clear need for additional treatment options for patients with advanced prostate cancer, especially options with the potential to provide greater efficacy with minimal toxicity. One such treatment option utilizes the power of the patient's own immune system to recognize and fight the malignant prostate cancer cells. The strategy of therapeutic vaccines in prostate cancer treatment has been actively pursued in recent years. In this monograph, we will review the role of GVAX® immunotherapy for prostate cancer, a cancer immunotherapy utilizing irradiated whole tumor cells genetically modified to secrete an important immunostimulating cytokine, human granulocyte-macrophage colony-stimulating factor (GM-CSF).

UR - http://www.scopus.com/inward/record.url?scp=76649084896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649084896&partnerID=8YFLogxK

U2 - 10.1358/dof.2009.034.01.1317459

DO - 10.1358/dof.2009.034.01.1317459

M3 - Review article

AN - SCOPUS:76649084896

VL - 34

SP - 16

EP - 22

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 1

ER -